Response with low-dose ponatinib is similar to that of standard-dose ponatinib among patients with refractory chronic myeloid leukemia (CML).
Patients with chronic myeloid leukemia (CML) in accelerated phase may obtain less clinical benefit with first-line imatinib therapy.
Treatment with ibrutinib may be associated with favorable progression-free and overall survival as well as high overall response rate.
The FDA accepted a New Drug Application for neratinib for the extended treatment of patients with early HER2-positive breast cancer.
Treatment with single-agent dalantercept had favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma.
Bevacizumab should not be used with capecitabine as an adjuvant treatment for colorectal cancer.
The addition of rituximab to chemotherapy may benefit patients being treated for acute lymphoblastic leukemia (ALL).
In a large cohort of US veterans with multiple myeloma, statin therapy was associated with a decreased risk of all-cause and cancer-specific mortality.
Pneumonitis associated with PD-1/PD-L1 monoclonal antibodies is more common when given in combination with anti-CTLA-4 monoclonal antibodies.
Enrollment disparities in clinical trials improved between 1990 and 2012 for female and elderly patients with lung cancer.
Primary G-CSF was associated with low-to-modest benefit in lowering risk for neutropenia-related hospitalization.
CTA has updated its treatment regimen chart for the treatment of esophageal and esophagogastric junction cancers.
Study findings support further evaluation of fixed-dose pembrolizumab for patients with recurrent and/or metastatic HNSCC.
Study findings suggest that continuous low-dose cyclophosphamide with lenalidomide and prednisone is a potential multidrug therapeutic strategy for patients with refractory multiple myeloma.
Vasectomy is not linked to either prostate cancer incidence or likelihood of developing aggressive prostate cancer.
Following USPSTF recommendations, there has been a decrease in utilization of digital rectal examination and PSA testing,
There was a decrease in cancer mortality from 1999 to 2014 for children and adolescents aged 1 to 19 years.
For hypogonadal men with prostate cancer, testosterone treatment seems oncologically safe.
Ricolinostat appears to be safe and well tolerated among patients with relapsed or refractory multiple myeloma.
Massage therapy may reduce peripheral neuropathy symptoms among patients receiving neurotoxic chemotherapy.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Massage Therapy May Reduce Chemo-induced Peripheral Neuropathy
- Statins Linked to Improved Overall Survival in Multiple Myeloma
- 2016 Concordia Summit: The Future of Immunotherapy
- Oral REP Regimen Active in Myeloma Refractory to Lenalidomide
- Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC
- Response Rate Similar Between Low- and Standard-dose Ponatinib
- Imatinib Less Beneficial for Patients With CML in Accelerated Phase
- Ibrutinib Linked With Favorable Survival, High Response Rate in CLL
- Q&A With Dr Sarah Vinnicombe: Use Breast MRI Judiciously for Optimal Outcomes
- Ghost and Honorary Authorship in Cancer Research